7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine
• 英文别名: sitagliptin；(3-Des-trifluoromethyl-3-methyl) Sitagliptin；(3R)-3-amino-1-(3-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-4-(2,4,5-trifluorophenyl)butan-1-one
• 化学式: C₁₆H₁₈F₃N₅O
• 分子量: 353.347
• InChiKey: URAMUGLEQXVDEP-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  77
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  丁二酸 、 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine 以 甲醇 为溶剂， 反应 1.0h， 以70%的产率得到sitagliptin succinate
  参考文献：
  名称：

  [EN] AMORPHOUS FORM OF SITAGLIPTIN SALTS
  [FR] FORME AMORPHE DE SELS DE SITAGLIPTINE

  摘要：

  公开号：

  WO2013084210A9

文献信息

• INTERMEDIATES OF SITAGLIPTIN AND PREPARATION PROCESS THEREOF
  申请人：Pan Xianhua

  公开号：US20130281695A1

  公开（公告）日：2013-10-24

  Disclosed are intermediates of Sitagliptin, a preparation process thereof, and a process for synthesizing Sitagliptin using these intermediates. Sitagliptin is synthesized by using chiral amino compounds as a raw material, without having to build a chiral center with a chiral asymmetric catalytic hydrogenation, and high-pressure hydrogenation is avoided.

  揭示了西他列汀的中间体、其制备过程以及利用这些中间体合成西他列汀的方法。西他列汀是通过使用手性氨基化合物作为原料合成的，无需通过手性不对称催化氢化建立手性中心，并且避免了高压氢化反应。
• SITAGLIPTIN INTERMEDIATES, PREPARATION METHODS AND USES THEREOF
  申请人：Zhu Guoliang

  公开号：US20120178957A1

  公开（公告）日：2012-07-12

  The present invention relates to Sitagliptin intermediate and preparation method and use thereof. The method comprises reacting compound of formula (II) and trifluorobromobenzene with a Grignard reagent by a Grignard reaction to obtain a compound of formula (I). Compound of formula (I) is a new intermediate compound for the synthesis of Sitagliptin. Compound of formula (I) can be easily used for preparing another important intermediate compound of formula (V) for the synthesis of Sitagliptin. The structures of the compounds mentioned above are as the following:

  本发明涉及Sitagliptin中间体及其制备方法和用途。该方法包括通过Grignard反应将式（II）化合物和三氟溴苯与Grignard试剂反应，以获得式（I）化合物。式（I）化合物是合成Sitagliptin的新中间体化合物。式（I）化合物可轻松用于制备另一重要的中间体化合物（V）以合成Sitagliptin。上述化合物的结构如下：
• PROCESS FOR THE PREPARATION OF SITAGLIPTIN PHOSPHATE
  申请人：CADILA HEALTHCARE LIMITED

  公开号：US20150087834A1

  公开（公告）日：2015-03-26

  The present invention relates to a method for the preparation of sitagliptin phosphate and sitagliptin phosphate anhydrous of Formula (I′) and monohydrate of Formula (I),

  本发明涉及一种制备西格列汀磷酸盐、无水西格列汀磷酸盐（I'式）和一水合物（I式）的方法。
• PROCESS FOR THE PRODUCTION OF SITAGLIPTIN
  申请人：Rasparini Marcello

  公开号：US20140081026A1

  公开（公告）日：2014-03-20

  A novel process is described for the synthesis of Sitagliptin, IUPAC name 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine, of formula (I).

  本文描述了一种合成西格列汀的新工艺，IUPAC名称为7-[(3R)-3-amino-1-oxo-4-(2,4,5-三氟苯基)丁基]-5,6,7,8-四氢-3-(三氟甲基)-1,2,4-三唑并[4,3-a]吡嗪，其化学式为(I)。
• BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20130217695A1

  公开（公告）日：2013-08-22

  The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种双肽酶-IV酶（“DP-IV酶”）抑制剂化合物，可用于治疗或预防与双肽酶-IV酶有关的疾病，例如糖尿病，特别是2型糖尿病。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗与双肽酶-IV酶有关的疾病中的使用。